Effects of Recombinant Human Brain Natriuretic Peptide in Patients with Acute Pulmonary Embolism Complicated with Right Ventricular Dysfunction Who Underwent Catheter-Directed Therapy
Authors:
- 29 January 2022
- journal article
- research article
- Published by International Heart Journal (Japanese Heart Journal) in International Heart Journal
- Vol. 63 (1) , 8-14
Abstract
Acute pulmonary embolism (PE) remains a significant cause of cardiovascular morbidity and mortality worldwide. Brain natriuretic peptide (BNP) combined with catheter-directed therapy (CDT) may improve right ventricular (RV) dysfunction and stabilize hemodynamics in acute PE. We retrospectively studied 159 patients with confirmed acute PE who were treated with CDT and admitted to the intensive care unit of our department between September 2016 and May 2020. The patients were divided into the control group and the rhBNP group based on whether to receive recombinant human BNP treatment (rhBNP) or not. The basic characteristics of the patients between the control group and the rhBNP group was systematically compared during admission and follow-up. Risk factors for all-cause mortality within 30 days were determined using multivariate logistic regression analysis. Respiratory rate was found to be significantly lower in the rhBNP group than in the control group. Patients in the rhBNP group had significantly lower levels of white blood cell, C-reactive protein (CRP), D-dimers, troponin I, creatinine, and N-terminal (NT) -proBNP compared with those in the control group. Levels of tricuspid annular plane systolic excursion were significantly higher in the rhBNP group than in the control group. The percentage of patients with rehospitalization readmission due to PE differed significantly between the control group and the rhBNP group. On the basis of the multivariate regression analysis, CRP, creatinine, troponin I, and NT-proBNP were independent factors of all-cause mortality in 30 days. rhBNP is effective in the treatment of patients with RV dysfunction caused by acute PE who underwent CDT, which may be an alternative treatment option for improving clinical prognosis.Keywords
This publication has 42 references indexed in Scilit:
- Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolismThrombosis Research, 2010
- Low-dose nesiritide in human anterior myocardial infarction suppresses aldosterone and preserves ventricular function and structure: a proof of concept studyHeart, 2009
- Importance of Inflammation and Neurohumoral Activation in Takotsubo CardiomyopathyJournal of Cardiac Failure, 2009
- Disruption of phospholipase C 1 signalling attenuates cardiac tumor necrosis factor- expression and improves myocardial function during endotoxemiaCardiovascular Research, 2007
- Predictors of Major Hemorrhage Following Fibrinolysis for Acute Pulmonary EmbolismThe American Journal of Cardiology, 2006
- Effects of Intravenous Nesiritide on Human Coronary Vasomotor Regulation and Myocardial Oxygen UptakeCirculation, 2003
- Low Pro-Brain Natriuretic Peptide Levels Predict Benign Clinical Outcome in Acute Pulmonary EmbolismCirculation, 2003
- Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failureJACC, 1999
- Echocardiography Doppler in pulmonary embolism: Right ventricular dysfunction as a predictor of mortality rateAmerican Heart Journal, 1997
- Volume Expansion versus Norepinephrine in Treatment of a Low Cardiac Output Complicating an Acute Increase in Right Ventricular Afterload in DogsAnesthesiology, 1984